

# Natasha B Leigh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3951331/publications.pdf>

Version: 2024-02-01

322  
papers

28,534  
citations

14614

66  
h-index

5965

160  
g-index

323  
all docs

323  
docs citations

323  
times ranked

32168  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab for the Treatment of Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	13.9	5,183
2	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
3	Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Nonâ€“Small-Cell Lung Cancer: AVAiL. <i>Journal of Clinical Oncology</i> , 2009, 27, 1227-1234.	0.8	1,430
4	Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. <i>Lancet</i> , 2014, 383, 1721-1730.	6.3	1,361
5	Five-Year Overall Survival for Patients With Advanced Nonâ€“Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	0.8	811
6	Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 3199-3212.	0.8	680
7	Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <i>Nature</i> , 2018, 563, 579-583.	13.7	624
8	CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>i&gt;EGFR&lt;/i&gt;-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i>, 2018, 36, 3290-3297.</i>	0.8	515
9	Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinaseâ€“Positive Nonâ€“Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 2490-2498.	0.8	506
10	Systemic Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3484-3515.	0.8	492
11	Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. <i>Nature Genetics</i> , 2017, 49, 1126-1132.	9.4	472
12	Communicating With Realism and Hope: Incurable Cancer Patients' Views on the Disclosure of Prognosis. <i>Journal of Clinical Oncology</i> , 2005, 23, 1278-1288.	0.8	463
13	Cancer Patient Preferences for Communication of Prognosis in the Metastatic Setting. <i>Journal of Clinical Oncology</i> , 2004, 22, 1721-1730.	0.8	428
14	Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Nonâ€“small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4691-4700.	3.2	401
15	Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 311-319.	0.8	387
16	Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature. <i>Journal of Clinical Oncology</i> , 2005, 23, 2926-2936.	0.8	335
17	Amivantamab in EGFR Exon 20 Insertionâ€“Mutated Nonâ€“Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3391-3402.	0.8	320
18	Therapy for Stage IV Nonâ€“Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1608-1632.	0.8	301

#	ARTICLE	IF	CITATIONS
19	Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non-Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 54-59.	0.8	290
20	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1647-1662.	0.5	274
21	Perceptions of palliative care among patients with advanced cancer and their caregivers. <i>Cmaj</i> , 2016, 188, E217-E227.	0.9	264
22	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3673-3679.	0.8	251
23	Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1413-1418.	0.8	240
24	Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non-Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 49-55.	0.8	231
25	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	3.6	211
26	Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1040-1091.	0.8	192
27	Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1415-1421.	0.6	187
28	The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. <i>Cancer Treatment Reviews</i> , 2016, 45, 139-162.	3.4	187
29	Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2017, 111, 23-29.	0.9	160
30	Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. <i>Journal of Clinical Oncology</i> , 2005, 23, 2831-2839.	0.8	159
31	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq1 1 0.784314 rgBT /Overl 1523-1531.	5.1	158
32	Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 404-410.	0.8	144
33	Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS. <i>Frontiers in Oncology</i> , 2014, 4, 204.	1.3	137
34	Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1628-1639.	0.5	137
35	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	5.2	137
36	Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1610-1623.	5.1	136

#	ARTICLE	IF	CITATIONS
37	Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 468-475.	0.4	124
38	Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1379-1388.	5.1	119
39	Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-“Small-Cell Lung Cancer: CheckMate 153. <i>Journal of Clinical Oncology</i> , 2020, 38, 3863-3873.	0.8	119
40	A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 397-402.	0.5	117
41	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	2.0	115
42	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1210-1222.	0.5	112
43	<i>EGFR</i> gene status in cytological samples of nonsmall cell lung carcinoma. <i>Cancer Cytopathology</i> , 2011, 119, 80-91.	1.4	107
44	Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAL). <i>Journal of Thoracic Oncology</i> , 2010, 5, 1970-1976.	0.5	105
45	KRAS Mutations as Prognostic and Predictive Markers in Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 530-542.	0.5	104
46	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, 426-434.e1.	1.1	102
47	Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 404-415.	0.5	102
48	Targeting the KRAS Pathway in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 1450-1460.	1.9	101
49	Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma. <i>Journal of Clinical Oncology</i> , 2010, 28, 3316-3322.	0.8	96
50	Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2077-2084.	0.8	95
51	Mechanisms of osimertinib resistance and emerging treatment options. <i>Lung Cancer</i> , 2020, 147, 123-129.	0.9	95
52	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in <i>EGFR</i> -Mutant Lung Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2472-2480.	0.8	94
53	Phase II Study of Preoperative Gefitinib in Clinical Stage I Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 6229-6236.	0.8	93
54	Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?. <i>Journal of Thoracic Oncology</i> , 2013, 8, 366-368.	0.5	91

#	ARTICLE	IF	CITATIONS
55	Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 2241-7.	3.2	90
56	A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1379-1391.	0.5	89
57	A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1054-1059.	0.5	84
58	Discussing Adjuvant Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2001, 19, 1768-1778.	0.8	83
59	Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now. <i>Journal of Clinical Oncology</i> , 2014, 32, 3330-3336.	0.8	80
60	Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 810-815.	0.8	79
61	ALK -Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. <i>Clinical Lung Cancer</i> , 2017, 18, 156-161.	1.1	78
62	Impact and Feasibility of a Comprehensive Geriatric Assessment in the Oncology Setting. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 322-328.	0.6	77
63	Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer. <i>Chest</i> , 2005, 128, 2933-2943.	0.4	74
64	A Phase 2 study of perifosine in advanced or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008, 108, 87-92.	1.1	73
65	Venous thromboembolism and nonsmall cell lung cancer. <i>Cancer</i> , 2009, 115, 5516-5525.	2.0	72
66	Sample Features Associated with Success Rates in Population-Based EGFR Mutation Testing. <i>Journal of Thoracic Oncology</i> , 2014, 9, 947-956.	0.5	72
67	Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?. <i>Cancer</i> , 2015, 121, 2562-2569.	2.0	71
68	Pointed Progress in Second-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. <i>Journal of Clinical Oncology</i> , 2016, 34, 1676-1688.	0.8	71
69	Determinants of quality of life in patients with advanced cancer. <i>Supportive Care in Cancer</i> , 2011, 19, 621-629.	1.0	70
70	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP) Tj ETQq0 0 0 rgBT <sub>1</sub> /Overlock 10 Tf 50	3.1	68
71	A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium. <i>Oncologist</i> , 2010, 15, 810-818.	1.9	66
72	Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , 2010, 102, 298-306.	3.0	64

#	ARTICLE	IF	CITATIONS
73	Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade. <i>Clinical Lung Cancer</i> , 2017, 18, 274-280.e6.	1.1	63
74	Therapy for Stage IV Non-“Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 3323-3343.	0.8	63
75	An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on Access. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e1-e12.	1.8	62
76	Therapy for Stage IV Non-“Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 3310-3322.	0.8	60
77	Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. <i>Oncologist</i> , 2017, 22, 70-80.	1.9	58
78	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1368.	3.4	57
79	Derivation of Utility Values from European Organization for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire Values in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1953-1957.	0.5	56
80	Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?. <i>Journal of Clinical Oncology</i> , 2017, 35, 2764-2771.	0.8	56
81	Treatment of the Elderly When Cure is the Goal: The Influence of Age on Treatment Selection and Efficacy for Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 537-544.	0.5	55
82	Patients with Advanced Non-“Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 79-84.	0.5	54
83	Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 1344-1352.	0.8	51
84	Does Intensive Follow-up Alter Outcome in Patients with Advanced Lung Cancer?. <i>Journal of Thoracic Oncology</i> , 2007, 2, 273-281.	0.5	51
85	TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. <i>Cancer Cell</i> , 2020, 37, 742-745.	7.7	51
86	Third-Line Chemotherapy in Small-Cell Lung Cancer: An International Analysis. <i>Clinical Lung Cancer</i> , 2014, 15, 110-118.	1.1	49
87	Utilization of prophylactic cranial irradiation in patients with limited stage small cell lung carcinoma. <i>Cancer</i> , 2010, 116, 5694-5699.	2.0	48
88	Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-“small cell lung cancer: A real-world multicentre study. <i>European Journal of Cancer</i> , 2021, 142, 83-91.	1.3	48
89	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 561-572.	5.2	47
90	Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, 253-259.	1.1	47

#	ARTICLE	IF	CITATIONS
91	Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 113.	1.3	46
92	Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non-Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 2256-2261.	0.8	45
93	Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1449-1458.	0.5	45
94	Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 125, 49-57.	1.3	45
95	Shifting Patterns in the Interpretation of Phase III Clinical Trial Outcomes in Advanced Non-Small-Cell Lung Cancer: The Bar Is Dropping. <i>Journal of Clinical Oncology</i> , 2014, 32, 1407-1411.	0.8	44
96	Treatment Decision Aids in Advanced Cancer: When the Goal Is Not Cure and the Answer Is Not Clear. <i>Journal of Clinical Oncology</i> , 2004, 22, 1759-1762.	0.8	43
97	Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 39-43.	0.5	43
98	Clinical Outcomes of Extensive Stage Small Cell Lung Carcinoma Patients Treated With Consolidative Thoracic Radiotherapy. <i>Clinical Lung Cancer</i> , 2011, 12, 375-379.	1.1	43
99	Enhancing decision making about participation in cancer clinical trials: development of a question prompt list. <i>Supportive Care in Cancer</i> , 2011, 19, 1227-1238.	1.0	43
100	Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 123, 195-202.	0.3	43
101	Challenges to Implementation of an Epidermal Growth Factor Receptor Testing Strategy for Non-Small-Cell Lung Cancer in a Publicly Funded Health Care System. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1136-1141.	0.5	42
102	A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 457-465.	1.1	41
103	A Phase II Study of Telisotuzumab Vedotin in Patients With MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , 2021, 22, 170-177.	1.1	41
104	Satisfaction with oncology care among patients with advanced cancer and their caregivers. <i>Quality of Life Research</i> , 2013, 22, 2341-2349.	1.5	40
105	Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. <i>Angiogenesis</i> , 2014, 17, 909-920.	3.7	40
106	Scientific Advances in Thoracic Oncology 2016. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1183-1209.	0.5	40
107	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 556-566.	0.5	40
108	Early Palliative Care and Its Role in Oncology: A Qualitative Study. <i>Oncologist</i> , 2016, 21, 1387-1395.	1.9	39

#	ARTICLE	IF	CITATIONS
109	Chemotherapy treatment decision-making experiences of older adults with cancer, their family members, oncologists and family physicians: a mixed methods study. <i>Supportive Care in Cancer</i> , 2017, 25, 879-886.	1.0	39
110	Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet†. <i>European Journal of Cardio-thoracic Surgery</i> , 2008, 33, 1129-1134.	0.6	38
111	Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 4268-4273.	0.8	38
112	A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2013, 14, 19-27.	1.1	38
113	Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System. <i>Clinical Lung Cancer</i> , 2019, 20, 231-236.	1.1	38
114	Long-Term Outcome after En Bloc Resection of Non-Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1538-1544.	0.5	36
115	Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 592-602.	2.9	36
116	Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer. <i>Health Expectations</i> , 2008, 11, 35-45.	1.1	35
117	Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 405-414.	1.4	35
118	Differential Role of Estrogen Receptor Beta in Early Versus Metastatic Non-small Cell Lung Cancer. <i>Hormones and Cancer</i> , 2012, 3, 93-100.	4.9	34
119	Surgery for malignant pleural mesothelioma after radiotherapy (SMART): final results from a single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 190-197.	5.1	34
120	Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. <i>Frontiers in Oncology</i> , 2014, 4, 329.	1.3	33
121	Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma. <i>European Respiratory Journal</i> , 2017, 49, 1601428.	3.1	33
122	Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients. <i>Lung Cancer</i> , 2020, 150, 159-163.	0.9	33
123	A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 51, 115-121.	0.9	32
124	A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non-Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium. <i>Clinical Lung Cancer</i> , 2014, 15, 52-57.	1.1	32
125	Chemotherapy and radiation treatment decision-making experiences of older adults with cancer: A qualitative study. <i>Journal of Geriatric Oncology</i> , 2018, 9, 47-52.	0.5	32
126	Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). <i>Supportive Care in Cancer</i> , 2013, 21, 165-172.	1.0	31



#	ARTICLE	IF	CITATIONS
127	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. Journal of Clinical Oncology, 2016, 34, 9026-9026.	0.8	31
128	Classification and Toxicities of Vascular Disrupting Agents. Clinical Lung Cancer, 2011, 12, 18-25.	1.1	30
129	Chemoradiotherapy for Locoregional Recurrence of Non-Small-Cell Lung Cancer After Surgical Resection: A Retrospective Analysis. Clinical Lung Cancer, 2013, 14, 200-204.	1.1	30
130	Barriers and Challenges to Global Clinical Cancer Research. Oncologist, 2014, 19, 61-67.	1.9	30
131	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. Frontiers in Oncology, 2017, 7, 50.	1.3	30
132	Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 64-77.	1.9	30
133	A drug discovery platform to identify compounds that inhibit EGFR triple mutants. Nature Chemical Biology, 2020, 16, 577-586.	3.9	30
134	Cost-Effectiveness Analysis Comparing Conventional Versus Stereotactic Body Radiotherapy for Surgically Ineligible Stage I Non-Small-Cell Lung Cancer. Journal of Oncology Practice, 2014, 10, e130-e136.	2.5	29
135	Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis, 2018, 39, 336-346.	1.3	29
136	Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor. Journal of Thoracic Oncology, 2015, 10, e100-e101.	0.5	28
137	The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer. Lung Cancer, 2018, 123, 22-29.	0.9	28
138	Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer. Lung Cancer, 2019, 134, 259-267.	0.9	28
139	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. Journal of Clinical Oncology, 2013, 31, 8028-8028.	0.8	28
140	Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.. Journal of Clinical Oncology, 2016, 34, 9044-9044.	0.8	28
141	Impact of New Chemotherapeutic and Targeted Agents on Survival in Stage IV Non-Small Cell Lung Cancer. Oncologist, 2011, 16, 1307-1315.	1.9	27
142	The Value of Personalizing Medicine: Medical Oncologists' Views on Gene Expression Profiling in Breast Cancer Treatment. Oncologist, 2015, 20, 351-356.	1.9	27
143	Correlation of Dosimetric and Clinical Factors With the Development of Esophagitis and Radiation Pneumonitis in Patients With Limited-Stage Small-Cell Lung Carcinoma. Clinical Lung Cancer, 2015, 16, 216-220.	1.1	27
144	Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2016, 11, 900-909.	0.5	27

#	ARTICLE	IF	CITATIONS
145	The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2019, 20, 21.	1.3	27
146	Indications for Adjuvant Mediastinal Radiotherapy in Surgically Resected Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1647-1653.	0.7	26
147	Development of the Functional Assessment of Cancer Therapyâ€œImmune Checkpoint Modulator (FACTâ€œICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	2.0	26
148	Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2040-2050.	0.5	26
149	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)., 2021, 9, e002973.		26
150	How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment. <i>BMJ Open</i> , 2016, 6, e010981.	0.8	25
151	Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development. <i>Oncotarget</i> , 2019, 10, 1760-1774.	0.8	25
152	Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9007-9007.	0.8	25
153	Genetic markers of bevacizumab-induced hypertension. <i>Angiogenesis</i> , 2014, 17, 685-94.	3.7	24
154	BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. <i>Lung Cancer</i> , 2020, 146, 78-85.	0.9	24
155	Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Nonâ€œSmall-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1830-1844.	0.5	23
156	Real-World EQ5D Health Utility Scores for Patients With Metastatic Lung Cancer by Molecular Alteration and Response to Therapy. <i>Clinical Lung Cancer</i> , 2017, 18, 388-395.e4.	1.1	23
157	Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensiveâ€œStage Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 981-992.	1.9	23
158	A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196. <i>Oncotarget</i> , 2017, 8, 69651-69662.	0.8	23
159	Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed for KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8027-8027.	0.8	22
160	Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 422-429.e1.	0.6	21
161	Cancer patientsâ€™ experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020, 9, 3015-3022.	1.3	21
162	Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. <i>Cancer Treatment Reviews</i> , 2020, 85, 101979.	3.4	21

#	ARTICLE	IF	CITATIONS
163	CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2022, 17, 434-445.	0.5	21
164	Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 829, 45-49.	1.2	20
165	Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline. <i>Journal of Oncology Practice</i> , 2015, 11, 135-136.	2.5	20
166	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer. <i>JAMA Network Open</i> , 2021, 4, e2117547.	2.8	20
167	Lung cancer in never smokers from the Princess Margaret Cancer Centre. <i>Oncotarget</i> , 2018, 9, 22559-22570.	0.8	20
168	Anticoagulation and Bleeding: A Pooled Analysis of Lung Cancer Trials of the NCIC Clinical Trials Group. <i>Journal of Thoracic Oncology</i> , 2009, 4, 586-594.	0.5	18
169	Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non-Small-Cell Lung Cancer: A California Cancer Consortium Trial. <i>Clinical Lung Cancer</i> , 2011, 12, 33-37.	1.1	18
170	P2.39: Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab. <i>Journal of Thoracic Oncology</i> , 2016, 11, S241-S242.	0.5	18
171	The Influence of Sex on Efficacy, Adverse Events, Quality of Life, and Delivery of Treatment in National Cancer Institute of Canada Clinical Trials Group Non-small Cell Lung Cancer Chemotherapy Trials. <i>Journal of Thoracic Oncology</i> , 2010, 5, 640-648.	0.5	17
172	Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients. <i>British Journal of Cancer</i> , 2016, 114, 616-622.	2.9	17
173	Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy. <i>Journal of Thoracic Disease</i> , 2015, 7, 1898-906.	0.6	17
174	Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 72-81.	1.1	17
175	Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. <i>Lung Cancer</i> , 2006, 52, 327-332.	0.9	16
176	A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1163-1169.	0.5	16
177	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 563-571.	1.1	16
178	Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers. <i>Cancer Medicine</i> , 2014, 3, 426-433.	1.3	16
179	Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0121211.	1.1	16
180	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. <i>Pharmacoeconomics</i> , 2017, 35, 1195-1209.	1.7	16

#	ARTICLE	IF	CITATIONS
181	Additional germline findings from a tumor profiling program. <i>BMC Medical Genomics</i> , 2018, 11, 65.	0.7	16
182	Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 2043-2054.e9.	0.4	16
183	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?—current evidence and future perspectives. <i>Translational Lung Cancer Research</i> , 2016, 5, 628-636.	1.3	15
184	Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non—small-cell Lung Cancer (NCT02788461). <i>Clinical Lung Cancer</i> , 2018, 19, e699-e703.	1.1	15
185	Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study. <i>CMAJ Open</i> , 2020, 8, E191-E198.	1.1	15
186	E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8507-8507.	0.8	15
187	Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. <i>Radiotherapy and Oncology</i> , 2012, 102, 263-267.	0.3	14
188	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. <i>Value in Health</i> , 2012, 15, 580-585.	0.1	14
189	A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 747-755.	1.1	14
190	Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population—based reflex testing. <i>Cancer</i> , 2019, 125, 4043-4051.	2.0	14
191	Real—world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non—small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 7542-7555.	1.3	14
192	The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. <i>Lung Cancer</i> , 2019, 131, 86-89.	0.9	14
193	Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non—small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e338-e345.	1.1	14
194	Molecular testing for lung adenocarcinoma: Is it time to adopt a —plasma—first—approach?. <i>Cancer</i> , 2020, 126, 3176-3180.	2.0	14
195	ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. <i>Lung Cancer</i> , 2020, 146, 350-354.	0.9	14
196	Consensus Recommendations to Optimize Testing for New Targetable Alterations in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4981-4997.	0.9	14
197	Pembrolizumab for the treatment of thoracic malignancies: current landscape and future directions. <i>Future Oncology</i> , 2016, 12, 9-23.	1.1	13
198	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019, 4, e000532.	2.0	13

#	ARTICLE	IF	CITATIONS
199	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020, 126, 1530-1540.	2.0	13
200	Docetaxel in Non-Small Cell Lung Cancer. <i>Drugs and Aging</i> , 2007, 24, 411-428.	1.3	12
201	How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , 2011, 12, 1-11.	1.3	12
202	Do Economic Evaluations of Targeted Therapy Provide Support for Decision Makers?. <i>Journal of Oncology Practice</i> , 2011, 7, 36s-45s.	2.5	12
203	Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases. <i>Advances in Radiation Oncology</i> , 2020, 5, 350-357.	0.6	12
204	Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer: A Cost-Efficient Strategy in a Public Healthcare System. <i>Current Oncology</i> , 2021, 28, 3268-3279.	0.9	12
205	A Phase I Study of Pegylated Liposomal Doxorubicin Hydrochloride (Caelyx) in Combination with Cyclophosphamide and Vincristine as Second-Line Treatment of Patients with Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2003, 5, 107-112.	1.1	11
206	A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 84, 289-294.	0.9	11
207	P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1167-S1169.	0.5	11
208	Investigation of Leukocyte Telomere Length and Genetic Variants in Chromosome 5p15.33 as Prognostic Markers in Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1228-1237.	1.1	11
209	Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?. <i>Oncologist</i> , 2021, 26, 56-62.	1.9	11
210	Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 133-141.	1.1	10
211	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. <i>CNS Drugs</i> , 2018, 32, 527-542.	2.7	10
212	Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma. <i>Oncologist</i> , 2019, 24, e510-e517.	1.9	10
213	The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective. <i>Cancer Cytopathology</i> , 2019, 127, 72-78.	1.4	10
214	Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 2706-2712.	0.6	10
215	Second-Line Therapy in Non-Small-Cell Lung Cancer: The DELTA Between Different Genotypes Widens. <i>Journal of Clinical Oncology</i> , 2014, 32, 1874-1881.	0.8	9
216	Multicenter Validation Study to Implement Plasma Epidermal Growth Factor Receptor T790M Testing in Clinical Laboratories. <i>JCO Precision Oncology</i> , 2020, 4, 520-533.	1.5	9

#	ARTICLE	IF	CITATIONS
217	Cluster-randomized trial of early palliative care for patients with metastatic cancer.. Journal of Clinical Oncology, 2012, 30, 9003-9003.	0.8	9
218	End-of-life home care utilization and costs in patients with advanced colorectal cancer. Journal of Community and Supportive Oncology, 2014, 12, 92-98.	0.1	9
219	A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget, 2016, 7, 25632-25639.	0.8	9
220	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. Journal of Thoracic Oncology, 2022, 17, 661-674.	0.5	9
221	BRM Promoter Polymorphisms and Survival of Advanced Nonâ€“Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. Clinical Cancer Research, 2017, 23, 2460-2470.	3.2	8
222	Translation of Knowledge to Practiceâ€“Improving Awareness in NSCLC Molecular Testing. Journal of Thoracic Oncology, 2018, 13, 1004-1011.	0.5	8
223	The Impact of Brain Metastases and Associated Neurocognitive Aspects on Health Utility Scores in EGFR Mutated and ALK Rearranged NSCLC: A Real World Evidence Analysis. Oncologist, 2019, 24, e501-e509.	1.9	8
224	Evan's Syndrome Associated with Pembrolizumab Therapy in Metastatic Non-Small Cell Lung Cancer. Blood, 2015, 126, 4543-4543.	0.6	8
225	Economic evaluation of docetaxel for breast cancer. Expert Opinion on Pharmacotherapy, 2009, 10, 283-290.	0.9	7
226	ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients. Cancer Epidemiology, 2016, 41, 50-56.	0.8	7
227	Lorlatinib in ALK-Rearranged Lung Cancer. Cancer Cell, 2021, 39, 25-27.	7.7	7
228	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. Lung Cancer, 2021, 156, 76-81.	0.9	7
229	Systemic Inflammatory Markers of Survival in Epidermal Growth Factorâ€“Mutated Nonâ€“Small-Cell Lung Cancer: Single-Institution Analysis, Systematic Review, and Meta-analysis. Clinical Lung Cancer, 2021, 22, 390-407.	1.1	7
230	Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.. Journal of Clinical Oncology, 2016, 34, e20522-e20522.	0.8	7
231	Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget, 2017, 8, 57528-57536.	0.8	7
232	Improved compliance with adjuvant vinorelbine and cisplatin in non-small cell lung cancer. Hematology/ Oncology and Stem Cell Therapy, 2009, 2, 265-271.	0.6	6
233	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). Cancer Chemotherapy and Pharmacology, 2012, 69, 815-824.	1.1	6
234	Radical Treatment of Stage II Nonâ€“small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes. Clinical Lung Cancer, 2018, 19, e11-e18.	1.1	6

#	ARTICLE	IF	CITATIONS
235	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	7.7	6
236	The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. <i>Quality of Life Research</i> , 2021, 30, 445-454.	1.5	6
237	Meeting Immunotherapy Resistance in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 187-190.	0.5	6
238	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. <i>ESMO Open</i> , 2016, 1, e000118.	2.0	6
239	The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110563.	1.4	6
240	Personalized medicine for non-small cell lung cancer: where are we now and where can we go?. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 81-82.	1.0	5
241	Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib. <i>Clinical Lung Cancer</i> , 2020, 21, e488-e492.	1.1	5
242	The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy. <i>Current Drug Targets</i> , 2018, 20, 81-86.	1.0	5
243	Closing the personalized medicine information gap: HER2 test documentation practice. <i>American Journal of Managed Care</i> , 2013, 19, 838-44.	0.8	5
244	Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients. <i>Current Oncology</i> , 2021, 28, 5278-5294.	0.9	5
245	Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. <i>Current Oncology</i> , 2022, 29, 4428-4437.	0.9	5
246	Cost-Effectiveness of Chemotherapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 3750-3752.	0.8	4
247	Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine. <i>Frontiers in Oncology</i> , 2014, 4, 258.	1.3	4
248	A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, e41-e47.	1.1	4
249	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	1.4	4
250	The effect of prior cancer on non-small cell lung cancer trial eligibility. <i>Cancer Medicine</i> , 2021, 10, 4814-4822.	1.3	4
251	Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. <i>Neuro-Oncology Practice</i> , 2022, 9, 50-58.	1.0	4
252	Chemical Genetics Screen Identifies COPB2 Tool Compounds That Alters ER Stress Response and Induces RTK Dysregulation in Lung Cancer Cells. <i>Journal of Molecular Biology</i> , 2021, 433, 167294.	2.0	4

#	ARTICLE	IF	CITATIONS
253	Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. <i>Current Oncology</i> , 2021, 28, 4552-4576.	0.9	4
254	Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data. <i>Oncologist</i> , 2022, 27, 675-684.	1.9	4
255	Nazartinib for treatment-naïve EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study. <i>European Journal of Cancer</i> , 2022, 172, 276-286.	1.3	4
256	Initial Treatment Strategies and Outcomes for Multifocal Bronchioloalveolar Carcinoma. <i>Clinical Lung Cancer</i> , 2009, 10, 187-192.	1.1	3
257	Targeting Vascular Endothelial Growth Factor in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, S484-S486.	0.5	3
258	Targeting the Phosphatidylinositol 3-Kinase, Akt, and Mammalian Target of Rapamycin Pathway in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, S1805-S1807.	0.5	3
259	Sunitinib: The Next Advance in Small-Cell Lung Cancer?. <i>Journal of Clinical Oncology</i> , 2015, 33, 1637-1639.	0.8	3
260	The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy. <i>European Journal of Cancer</i> , 2016, 61, 85-93.	1.3	3
261	Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients. <i>Journal of Oncology Practice</i> , 2017, 13, 780-783.	2.5	3
262	A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7541-7541.	0.8	3
263	The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10522-10522.	0.8	3
264	Concurrent chemoradiation with or without durvalumab in elderly patients with unresectable stage 3 non-small cell lung cancer: safety and efficacy. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100251.	0.6	3
265	Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system. <i>Cancer Treatment and Research Communications</i> , 2022, 31, 100534.	0.7	3
266	Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1783.	1.3	2
267	Advancing the systemic therapy of lung cancer: quality or quantity?. <i>Lancet Oncology</i> , The, 2020, 21, 322-324.	5.1	2
268	Minimization of resource utilization data collected within cost-effectiveness analyses conducted alongside Canadian Cancer Trials Group phase III trials. <i>Clinical Trials</i> , 2021, 18, 500-504.	0.7	2
269	Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre. <i>Clinical Lung Cancer</i> , 2021, , .	1.1	2
270	Second and later-line erlotinib use in non-small cell lung cancer: real world outcomes and practice patterns overtime in Canada. <i>Journal of Thoracic Disease</i> , 2021, 13, 5419-5429.	0.6	2



#	ARTICLE	IF	CITATIONS
271	Predictive value of coexisting KRAS and TP53 mutations on response to chemotherapy in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 11060-11060.	0.8	2
272	Incidental germline findings identified in a somatic genomic sequencing program for advanced cancer patients.. Journal of Clinical Oncology, 2016, 34, 1532-1532.	0.8	2
273	Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review. Cancers, 2021, 13, 5299.	1.7	2
274	End-to-End Non-“Small-Cell Lung Cancer Prognostication Using Deep Learning Applied to Pretreatment Computed Tomography. JCO Clinical Cancer Informatics, 2021, 5, 1141-1150.	1.0	2
275	Importance of tumor size in resectable stage III-N2 non-“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 629-636.	0.4	2
276	Factors Contributing to Adjuvant Therapy Decisions. Journal of Thoracic Oncology, 2008, 3, 195-196.	0.5	1
277	Reply to C.G. Azzoli et al and C. Chouaid et al. Journal of Clinical Oncology, 2014, 32, 3578-3579.	0.8	1
278	Early-stage lung cancer-“what do the experts recommend?. Annals of Oncology, 2014, 25, 1451-1453.	0.6	1
279	Long-Term Outcome After Resection of Non-Small Cell Lung Cancer Invading the Thoracic Inlet. Annals of Thoracic Surgery, 2014, 98, 962-967.	0.7	1
280	Association of two <i>BRM</i> promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis. Molecular Carcinogenesis, 2019, 58, 1960-1973.	1.3	1
281	Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario. Journal of Oncology Pharmacy Practice, 2020, 26, 379-385.	0.5	1
282	Automated imaging-based stratification of early-stage lung cancer patients prior to receiving surgical resection using deep learning applied to CTs.. Journal of Clinical Oncology, 2021, 39, 1552-1552.	0.8	1
283	Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data. Clinical Lung Cancer, 2021, , .	1.1	1
284	Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.. Journal of Clinical Oncology, 2014, 32, TPS7612-TPS7612.	0.8	1
285	Health utility scores (HUS) and health-related quality of life (HRQoL) in stage 4 lung cancer (S4LC) patients with brain metastases (BM).. Journal of Clinical Oncology, 2017, 35, 24-24.	0.8	1
286	Cancer patients-™ and physicians-™ preferences for decision making regarding pharmacogenomic testing (PGT).. Journal of Clinical Oncology, 2012, 30, 13-13.	0.8	1
287	Willingness of patients to provide biologic samples for pharmacogenomic testing.. Journal of Clinical Oncology, 2013, 31, 6543-6543.	0.8	1
288	TCR clonality and Treg frequency as predictors of outcome in stage III NSCLC treated with durvalumab.. Journal of Clinical Oncology, 2020, 38, 3050-3050.	0.8	1

#	ARTICLE	IF	CITATIONS
289	Effects of Ethnicity on Outcomes of Patients With EGFR Mutation-Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100259.	0.6	1
290	PD6-1-7: A phase II study of UCN-01 in combination with topotecan in patients (pts) with chemosensitive relapsed small cell lung cancer (SCLC): a study of the Princess Margaret Hospital phase II consortium (PMH-C).. <i>Journal of Thoracic Oncology</i> , 2007, 2, S427.	0.5	0
291	PD3-2-5: Preoperative gefitinib in clinical stage I NSCLC. <i>Journal of Thoracic Oncology</i> , 2007, 2, S464.	0.5	0
292	Gefitinib: a consideration of cost. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2008, 8, 223-232.	0.7	0
293	Angiogenesis inhibitors in lung cancer: beyond VEGF?. <i>Lung Cancer Management</i> , 2012, 1, 7-10.	1.5	0
294	Gefitinib: re-emerging from the shadows. <i>Lung Cancer Management</i> , 2013, 2, 423-437.	1.5	0
295	Home care utilization and costs in stage IV lung cancer: a Canadian public payer experience. <i>Lung Cancer Management</i> , 2014, 3, 439-442.	1.5	0
296	Targeted therapy for lung cancer: reviewing the cost and its effect on treatment decisions. <i>Lung Cancer Management</i> , 2014, 3, 477-489.	1.5	0
297	Reply to G. Spitzer and M.A. Socinski. <i>Journal of Clinical Oncology</i> , 2015, 33, 525-526.	0.8	0
298	P1.07-017 Indications for Adjuvant Mediastinal Radiation in Surgically Resected Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S706.	0.5	0
299	P2.08-001 Giving a Voice to Patients and Caregivers through the Lung Cancer Canada "Faces of Lung Cancer" Survey. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1109.	0.5	0
300	P3.02c-076 Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1323-S1324.	0.5	0
301	OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. <i>Journal of Thoracic Oncology</i> , 2017, 12, S326-S327.	0.5	0
302	OA22.02 Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S329-S330.	0.5	0
303	P1.05-069 Stage II NSCLC Treated with Non-Surgical Approaches: A Multi-Institution Report of Outcomes. <i>Journal of Thoracic Oncology</i> , 2017, 12, S657-S658.	0.5	0
304	P1.06-039 Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant. <i>Journal of Thoracic Oncology</i> , 2017, 12, S689-S690.	0.5	0
305	P1.07-016 Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S705.	0.5	0
306	Curing Early-Stage Lung Cancer: Is There an Easy Way Out?. <i>Journal of Oncology Practice</i> , 2017, 13, 63-65.	2.5	0

#	ARTICLE	IF	CITATIONS
307	Improving the Management of Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer. <i>Journal of Oncology Practice</i> , 2019, 15, 571-572.	2.5	0
308	P3-120: Response rates of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) in clinical practice. <i>Journal of Thoracic Oncology</i> , 2007, 2, S730.	0.5	0
309	Venous Thromboembolism and Non-Small Cell Lung Cancer: A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Trials. <i>Blood</i> , 2007, 110, 3995-3995.	0.6	0
310	Population-Based Health Care Cost Estimates Related to Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2011, 118, 2068-2068.	0.6	0
311	Single nucleotide polymorphisms (SNPs) of the platinum pharmacogenetic and VEGF pathways: Association with survival of platinum-treated stage IV non-small cell lung cancer (NSCLC) patients. <i>Journal of Clinical Oncology</i> , 2012, 30, 7586-7586.	0.8	0
312	Genetic sequence variant (GSV) in TERT-CLPTM1L (5p15.33 locus) and survival in platinum-treated stage-IV non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2012, 30, 1535-1535.	0.8	0
313	Social environment as a predictor of smoking cessation and recidivism in lung cancer survivors. <i>Journal of Clinical Oncology</i> , 2012, 30, 9032-9032.	0.8	0
314	Central reporting of human epidermal growth factor receptor-2 (HER2) status and adherence to testing and adjuvant trastuzumab treatment guidelines in Ontario. <i>Journal of Clinical Oncology</i> , 2012, 30, 166-166.	0.8	0
315	Developing a comprehensive smoking cessation program in patients with lung cancer: The role of social smoking environments. <i>Journal of Clinical Oncology</i> , 2012, 30, 75-75.	0.8	0
316	Quality of life (QoL) for FDA-approved agents in advanced NSCLC. <i>Journal of Clinical Oncology</i> , 2016, 34, e18117-e18117.	0.8	0
317	A Phase I/IIb study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2609-TPS2609.	0.8	0
318	The economic impact of the transition from branded to generic oncology drugs. <i>Journal of Clinical Oncology</i> , 2016, 34, 6520-6520.	0.8	0
319	Real-world EQ5D health utility values for metastatic lung cancer patients by molecular alteration and response to therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 6567-6567.	0.8	0
320	Expanding therapies for crizotinib refractory ALK-rearranged non-small cell lung cancer. <i>Translational Cancer Research</i> , 2016, 5, S458-S461.	0.4	0
321	Feasibility of collecting routine information for clinical and research purposes via electronic format questionnaire. <i>Journal of Clinical Oncology</i> , 2017, 35, 167-167.	0.8	0
322	The financial impact of cancer care on renal cancer patients. <i>Canadian Journal of Urology</i> , 2021, 28, 10762-10767.	0.0	0